Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons

Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons

Abstract Introduction Biologic disease-modifying anti-rheumatic drugs (bDMARDs), including certolizumab pegol (CZP), are effective treatment options for the management of non-radiographic spondyloarthritis (nr-axSpA). In the absence of head-to-head comparisons in nr-axSpA, we conducted a systematic...

Full description

Bibliographic Details
Main Authors: Nurullah Akkoç, Carlos H. Arteaga, Simone E. Auteri, Marissa Betts, Kyle Fahrbach, Mindy Kim, Sandeep Kiri, Binod Neupane, Karl Gaffney, Philip J. Mease
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-01-01
Series:Rheumatology and Therapy
Subjects:
Axial spondyloarthritis
Biologic DMARDs
Certolizumab pegol
Efficacy
Indirect treatment comparison
Online Access:https://doi.org/10.1007/s40744-022-00522-0

Internet

https://doi.org/10.1007/s40744-022-00522-0

Similar Items